Juul van den Reek
0000-0002-3642-2673
Radboudumc
11 papers found
Refreshing results…
National consensus on biologic dose reduction in psoriasis: a modified eDelphi procedure
Regaining adequate treatment responses in patients with psoriasis who discontinued dose reduction of adalimumab, etanercept or ustekinumab
Drug Survival, Safety, and Effectiveness of Biologics in Older Patients with Psoriasis: A Comparison with Younger Patients—A BioCAPTURE Registry Study
Risk of respiratory tract infections and serious infections in psoriasis patients treated with biologics: Results from the BioCAPTURE registry
Data‐driven prediction of biologic treatment responses in psoriasis: steps towards precision medicine
Unmet Personal Patient Needs in Psoriasis Patients with Low Disease Activity on Adalimumab, Etanercept or Ustekinumab
Dose Tapering of Biologics in Patients with Psoriasis: A Scoping Review
Two-year Follow-up of a Dose Reduction Strategy Trial of Biologics Adalimumab, Etanercept, and Ustekinumab in Psoriasis Patients in Daily Practice
The Skin May Clear But the Arthritis Won’t Disappear: Focusing on Concomitant and New-Onset Psoriatic Arthritis in a Daily Practice Cohort of Psoriasis Patients on Biologic Therapy
Predicting treatment success with biologics in psoriasis
Biologic treatment sequences for plaque psoriasis: a cost-utility analysis based on 10 years of Dutch real-world evidence from BioCAPTURE
Missing publications? Search for publications with a matching author name.